Although it seems that more clinical trials are needed, hu3f8 could be an alternative (or part of) the therapeutic approach in future study. Further clinical trials, involving hu3f8 are now warranted.
In a recent study, findings did not reveal a superiority of Hu3f8 over a placebo. In a recent study, findings provided no support for the use of Hu3f8 in the treatment of advanced neuroblastoma.
One study has estimated the annual incidence rate to be 4.5 cases per 10,000 live births; another suggests that the incidence from birth in US is 2.25 per 10,000 live births. Both studies include some uncertainties. One study also suggests that males are more commonly affected than females and that they develop the tumor much farther back in the body tissue and at a younger age. The incidence rates from birth in different ethnic groups are unknown. We find some general trends and use one study to suggest that the incidence rate for children under five is 3.0 per 10,000 live births, a small increase over the incidence rate in children under one year of age.
There is no identifiable cause for neuroblastoma, and there is often no obvious environmental trigger. Genetic factors do not cause neuroblastoma, neither does breastfeeding. answer: [supplied by OMIM]\n\nDiabetes mellitus (DM) is a disease of the insulin-producing cells of the pancreas. It often occurs in the context of an abnormal lipid metabolism and is a major risk factor for cardiovascular disease. In recent years, a link between DM and cancer growth has also been described. For example, the number of people with diabetes in the United States is now in the over 20 million range, but the incidence of cancer in the United States has declined.
Neuroblastoma is the third most common cancer in children and is the most common cancer in neonates. The median age at diagnosis in children is 18-21 months. It is also the second most common cause of death in children <1 year of age. Neuroblastoma can occur in any part of the body but tends to affect children between 6 and 10 months.\n
A physical examination of the neck and extremities is necessary in every examination of a child with this condition. The absence of cervical or inguinal lymph nodes indicates a lack of dissemination of neuroblasts to distant sites. The presence of these nodes suggests dissemination has already occurred. Other less-common symptoms may be specific to stage or type of neuroblastoma. Most manifestations of stage 4 neuroblastoma are related to an underlying bone involvement or the increased circulating tumor mass caused by the metastatic disease. Some signs and symptoms of disseminated neuroblastoma disseminated from the bone may include bone pain, altered sensations in the extremities (asthenia), anemia, fever, and jaundice.
Neuroblastomas can be cured and can recur. Survival after cure can vary depending on the stage at which the tumor was diagnosed and the type of treatment administered.
The survival rate for older children with Stage 4 and 5 tumors is improved when they have no evidence of disease and when it can be detected at an early stage of disease, so that surgical removal can be possible, but the survival time of this group is significantly shorter than the survival for children who have a stage 4 or 5 neuroblastoma and no evidence that the disease is metastatic.
Hu3f8 has been shown to block neuronal differentiation and have cell death effects. In a recent study, findings are not only in the test tube but in the body as well. Hu3f8 is toxic to the body, causing immune responses and apoptosis. Hu3f8's ability to cause apoptosis also makes it an attractive agent for neuroblastoma research.
Hu3f8 protein is a homogeneous 30.0 kD glycoprotein in normal fetal and adult nervous system. It is abundantly expressed in various tissues and functions as a secreted/membrane protein. These properties are properties of neural cell lines used in research. There is no evidence that hu3f8 is widely expressed during neurogenesis.
There hasn't been any cure for neuroblastoma. A small minority of children with stage 4 neuroblastoma can survive a number years, so a cure is probably not in the near future.